Clinical Trial Update: IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating IRX-2, cyclophosphamide, and pembrolizumab in recurrent or metastatic gastric or gastroesophageal junction cancer; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• IRX-2
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-23